Next Article in Journal
Non-Steroidal Anti-Inflammatory Drugs in Alzheimer's Disease and Parkinson's Disease: Reconsidering the Role of Neuroinflammation
Previous Article in Journal
The Pharmacogenomics of Anti-Hypertensive Therapy
Previous Article in Special Issue
Beta-Adrenergic Agonists
Pharmaceuticals 2010, 3(6), 1792-1811; doi:10.3390/ph3061792
Review

Role of Leukotrienes and Leukotriene Modifiers in Asthma

Received: 21 April 2010; in revised form: 13 May 2010 / Accepted: 31 May 2010 / Published: 2 June 2010
(This article belongs to the Special Issue Antiasthmatic Drugs)
View Full-Text   |   Download PDF [368 KB, uploaded 2 June 2010]   |   Browse Figures
Abstract: Leukotrienes (LTs), including cysteinyl LTs (CysLTs) and LTB4, are potent lipid mediators that are pivotal in the pathophysiology of asthma phenotypes. At least two receptor subtypes for CysLTs – CysLT1 and CysLT2 – have been identified. Most of the pathophysiological effects of CysLTs in asthma, including increased airway smooth muscle activity, microvascular permeability and airway mucus secretion, are mediated by the activation of the CysLT1 receptor. LTB4 may have a role in the development of airway hyperresponsiveness, severe asthma and asthma exacerbations. Although generally less effective than inhaled glucocorticoids, CysLT1 receptor antagonists can be given orally as monotherapy in patients with persistent mild asthma. In patients with more severe asthma, CysLT1 receptor antagonists can be combined with inhaled glucocorticoids. This therapeutic strategy improves asthma control and enables the dose of inhaled glucocorticoids to be reduced, while maintaining similar efficacy. The identification of subgroups of patients with asthma who respond to CysLT1 receptor antagonists is relevant for asthma management, as the response to these drugs is variable. The potential anti-remodeling effect of CysLT1 receptor antagonists might be important for preventing or reversing airway structural changes in patients with asthma. This review discusses the role of LTs in asthma and the therapeutic implications of the pharmacological modulation of the LT pathway for asthma.
Keywords: asthma; leukotrienes; cysteinyl-leukotrienes; leukotriene B4; leukotrienes receptor antagonists; inhaled glucocorticoids; airway inflammation asthma; leukotrienes; cysteinyl-leukotrienes; leukotriene B4; leukotrienes receptor antagonists; inhaled glucocorticoids; airway inflammation
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Montuschi, P. Role of Leukotrienes and Leukotriene Modifiers in Asthma. Pharmaceuticals 2010, 3, 1792-1811.

AMA Style

Montuschi P. Role of Leukotrienes and Leukotriene Modifiers in Asthma. Pharmaceuticals. 2010; 3(6):1792-1811.

Chicago/Turabian Style

Montuschi, Paolo. 2010. "Role of Leukotrienes and Leukotriene Modifiers in Asthma." Pharmaceuticals 3, no. 6: 1792-1811.


Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert